Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Polypeptide and trypsin tablet composition and application thereof

A composition and drug technology, applied in the field of preparation of the above-mentioned chemical products, can solve problems such as changing the properties of active proteins, increasing potential safety hazards, reducing protein activity, etc., achieving the effects of convenient equipment, easy promotion and application, and good stability

Active Publication Date: 2016-04-13
西安迪赛生物药业有限责任公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the high temperature compression usually required in the preparation of tablets, for protein-containing preparations, it is particularly easy to reduce the activity of the protein, so a larger amount of active protein needs to be added
Moreover, proteins denatured at high temperatures are more likely to cause allergic reactions, increasing potential safety hazards
[0003] For this reason, existing technologies such as Chinese Patent Application No. 200410030650.7 avoid high-temperature tableting by directly filling enteric-coated capsules, but this does not fundamentally change the properties of active proteins, especially the stability of long-term high-temperature storage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide and trypsin tablet composition and application thereof
  • Polypeptide and trypsin tablet composition and application thereof
  • Polypeptide and trypsin tablet composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] The preparation of embodiment 1 polypeptide of the present invention

[0025] After long-term research, the inventors have developed the polypeptide of the present invention and its optimized expression gene sequence in yeast, wherein the nucleotide of the gene is shown in SEQ ID NO: 1, and the amino acid sequence of the polypeptide of the present invention encoded by it is as follows Shown in SEQ ID NO: 2. We entrust Xi'an Xintong Pharmaceutical Research Co., Ltd. to synthesize the gene and clone it into yeast cells. The amplification product was double digested with EcoRI and XbaI and connected between the multiple cloning sites of EcoRI and XbaI of pPICZαA (available from Invitrogen). After being confirmed by sequencing, the positive plasmid was transformed into yeast GS115 strain (available from Invitrogen Company), positive yeast cells were screened out with Zeocin.

[0026] The constructed positive yeast cells were inoculated in 25ml seed medium, and cultured wi...

Embodiment 2

[0028] Embodiment 2 Stability study of the polypeptide of the present invention

[0029] Referring to the protease activity detection method described in Harrach et al. (JProteinChem, 14:41-52), respectively detect the effect of the polypeptide of the present invention prepared in Example 1 and the reference polypeptide prepared in high temperature storage for different times on the substrate L-Pyr-Phe-Leu- Hydrolytic activity of pNA. For the convenience of comparison, the activity of 1 mg of the control polypeptide stored at high temperature for 0 days (that is, taken out from the storage state at -20°C for detection immediately) was counted as 1, and the relative activities of 1 mg of different polypeptides stored under different conditions are shown in Table 1. shown.

[0030] The stability of table 1 polypeptide

[0031]

[0032] As can be seen from Table 1, the activity of an equivalent amount of polypeptide of the present invention and the wild-type control polypept...

Embodiment 3 2

[0033] The preparation of embodiment 3 two enzyme tablets

[0034] Take 502 grams of starch and 130 grams of lactose, add 50% (V / V) ethanol to make a soft material, granulate, dry at 45°C until the water content is less than 5% (W / W), pass through a 20-mesh sieve, That is, the ball core is obtained.

[0035] Get 90 grams of the polypeptide of the present invention prepared in Example 1, 48 grams of trypsin and 100 grams of rutin, mix evenly with 5 grams of silicon dioxide micropowder, 25 grams of microcrystalline cellulose and the above-mentioned ball core, press into tablets, and press into 1000 piece.

[0036] Get 160 grams of oprdry standard coating powder, dissolve in 4L of 75% (V / V) ethanol, and prepare enteric coating solution. The above-mentioned formed tablets are placed in the fluidized bed, start the fluidized bed, and spray the enteric coating solution to these formed tablets with atomizing nozzles, wherein the parameters of the fluidized bed setting are: bed temp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a novel polypeptide with an amino acid sequence as shown in SEQ ID NO:2 or obtained by adding, deleting and / or substituting one or more amino acid residues on the sequence as shown in SEQ ID NO:2. The invention further provides a pharmaceutical composition comprising the polypeptide, preferably a phlogenzym tablet which is used for relieving edema after trauma or operation, shortening blood clot coagulation time, relieving pains caused by swelling and inflammation, treating thrombophlebitis, inflammation of genitourinary tract, arthritis (for example chronic arthritis) or soft tissue rheumatism.

Description

technical field [0001] The present invention belongs to the technical field of proteins or polypeptides. Specifically, the present invention relates to novel polypeptides and pharmaceutical compositions thereof, preferably also pancreatin tablets composed of the same and other active ingredients. In addition, the present invention also relates to the preparation method and medical application of the above chemical products. Background technique [0002] Phlogenzym tablets, also known as two-enzyme tablets or pancreatin tablets, whose active ingredients are mainly composed of protein, are used to reduce post-traumatic and post-operative edema, shorten blood clot aggregation time, slow down swelling and pain caused by inflammation, and can be used for such as thrombosis Treatment of diseases such as phlebitis, genitourinary tract inflammation, arthritis (eg, chronic arthritis) and soft tissue rheumatism. However, since high-temperature compression is usually required in the p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N9/50C12N15/57C12N15/63A61K38/48A61P29/00A61P9/14A61P19/02
CPCC12N9/50
Inventor 吴建中
Owner 西安迪赛生物药业有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com